MCL1 as putative target in pancreatoblastoma

[1]  M. Mino‐Kenudson,et al.  A Case of Adult Pancreatoblastoma With Novel APC Mutation and Genetic Heterogeneity , 2021, Frontiers in Oncology.

[2]  C. von Kalle,et al.  Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers. , 2021, Cancer discovery.

[3]  Patrina S P Poh,et al.  MCL-1 gains occur with high frequency in lung adenocarcinoma and can be targeted therapeutically , 2020, Nature Communications.

[4]  T. Overbeck,et al.  Top-level MET gene copy number gain defines a subtype of poorly differentiated pulmonary adenocarcinomas with poor prognosis , 2020, Translational lung cancer research.

[5]  E. Van Cutsem,et al.  Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. , 2020, The Lancet. Oncology.

[6]  Young Hak Kim,et al.  MCL1 inhibition is effective against a subset of small-cell lung cancer with high MCL1 and low BCL-XL expression , 2020, Cell Death & Disease.

[7]  S. Fröhling,et al.  Metastatic adult pancreatoblastoma: Multimodal treatment and molecular characterization of a very rare disease. , 2020, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[8]  S. Park,et al.  Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study. , 2019, The Lancet. Oncology.

[9]  R. Huddart,et al.  Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. , 2019, The New England journal of medicine.

[10]  C. von Kalle,et al.  Defective homologous recombination DNA repair as therapeutic target in advanced chordoma , 2019, Nature Communications.

[11]  J. A. Hendricks,et al.  Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia , 2018, Nature Communications.

[12]  Sean P. Brown,et al.  Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in KRAS-Mutant Non-Small Cell Lung Cancer. , 2018, Cancer discovery.

[13]  Sean P. Brown,et al.  AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies. , 2018, Cancer discovery.

[14]  E. Olejniczak,et al.  A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia. , 2018, Cancer discovery.

[15]  P. Philip,et al.  Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  S. Miyano,et al.  Integrated Molecular Characterization of the Lethal Pediatric Cancer Pancreatoblastoma. , 2018, Cancer research.

[17]  C. von Kalle,et al.  Precision oncology based on omics data: The NCT Heidelberg experience , 2017, International journal of cancer.

[18]  J. Visvader,et al.  Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer , 2017, Science Translational Medicine.

[19]  A. Strasser,et al.  The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models , 2016, Nature.

[20]  T. Henkel,et al.  Impact of updated HER2 testing guidelines in breast cancer—re-evaluation of HERA trial fluorescence in situ hybridization data , 2015, Modern Pathology.

[21]  E. Wardelmann,et al.  MET Gene Copy Number Alterations and Expression of MET and Hepatocyte Growth Factor Are Potential Biomarkers in Angiosarcomas and Undifferentiated Pleomorphic Sarcomas , 2015, PloS one.

[22]  T. Zander,et al.  MET Amplification Status in Therapy-Naïve Adeno- and Squamous Cell Carcinomas of the Lung , 2014, Clinical Cancer Research.

[23]  J. Wolf,et al.  Fibroblast growth factor receptor 1 (FGFR1) amplification is a potential therapeutic target in small-cell lung cancer , 2014, Modern Pathology.

[24]  Peter E. Czabotar,et al.  Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy , 2013, Nature Reviews Molecular Cell Biology.

[25]  R. Büttner,et al.  Therapeutic strategies in male breast cancer: clinical implications of chromosome 17 gene alterations and molecular subtypes. , 2013, Breast.

[26]  T. Zander,et al.  Definition of a fluorescence in-situ hybridization score identifies high- and low-level FGFR1 amplification types in squamous cell lung cancer , 2012, Modern Pathology.

[27]  A. Pappo,et al.  Management of pancreatoblastoma in children and young adults. , 2012, Journal of pediatric hematology/oncology.

[28]  R. Büttner,et al.  Postradiation cutaneous angiosarcoma after treatment of breast carcinoma is characterized by MYC amplification in contrast to atypical vascular lesions after radiotherapy and control cases: clinicopathological, immunohistochemical and molecular analysis of 66 cases , 2012, Modern Pathology.

[29]  A. Ferrari,et al.  Pancreatoblastoma: a report from the European cooperative study group for paediatric rare tumours (EXPeRT). , 2011, European journal of cancer.

[30]  L. Pecciarini,et al.  HER2 Testing in Gastric Cancer , 2011, Advances in anatomic pathology.

[31]  H. Höfler,et al.  [Her2 testing in gastric cancer. What is different in comparison to breast cancer?]. , 2010, Der Pathologe.

[32]  A. Ferrari,et al.  Pancreatic tumors in children and adolescents: The Italian TREP project experience , 2010, Pediatric blood & cancer.

[33]  H. Kreipe,et al.  Her2-Diagnostik beim Magenkarzinom , 2010, Der Pathologe.

[34]  Derek Y. Chiang,et al.  The landscape of somatic copy-number alteration across human cancers , 2010, Nature.

[35]  J. Neoptolemos,et al.  Diagnosis, Treatment and Outcome of Pancreatoblastoma , 2004, Pancreatology.

[36]  C. Patte,et al.  Pancreatoblastoma in childhood: clinical course and therapeutic management of seven patients. , 2001, Medical and pediatric oncology.

[37]  D. Klimstra,et al.  Pancreatoblastoma. A clinicopathologic study and review of the literature. , 1995, The American journal of surgical pathology.

[38]  E. Jabs,et al.  Human and mouse chromosomal mapping of the myeloid cell leukemia-1 gene: MCL1 maps to human chromosome 1q21, a region that is frequently altered in preneoplastic and neoplastic disease. , 1994, Genomics.